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Collin C. Barker,1 Manza-A. Agovi,2 Brent Logan,2 Hillard M. Lazarus,3
Karen K. Ballen,4 Vikas Gupta,5 Gregory A. Hale,6 Haydar Frangoul,7 Vincent Ho,8
J. Douglas Rizzo,2 Marcelo C. Pasquini2 on behalf of the Regimen-Related Toxicity Writing
Committee, Center for International Blood and Marrow Transplant ResearchThe prevalence of obesity in the pediatric population has increased in the last 2 decades and represents a se-
rious health concern, with potential impact on outcomes of hematopoietic cell transplantation (HCT). We
studied the effect of weight by age-adjusted body mass index (BMI) percentile in 1,281 pediatric patients (age
2-19 years) with severe aplastic anemia who underwent HCT between 1990 and 2005. The study population
was divided into 5 weight groups—underweight, risk of underweight, normal BMI range, risk of overweight,
and overweight—according to age-adjusted BMI percentiles. Cox proportional hazards regression models
for survival and acute graft-versus-host disease (aGVHD), performed using weight groups as the main effect
and the normal BMI range (26th-75th percentile) as the baseline comparison, found higher mortality among
overweight children (.95th percentile adjusted for age). Weight at transplantation did not increase the
adjusted risk of grade III-IV aGVHD. The 1-year and 2-year overall survival rates were 60% and 59% for
overweight children, compared with.70% in children with lower BMI at both time points (P\.001). Other
significant factors associated with survival included race and region, donor type, conditioning regimens in
related donor transplants, performance score, and year of transplantation. In conclusion, overweight
children with aplastic anemia have worse outcomes after HCT. The impact of obesity on survival outcomes
in children should be discussed during pretransplantation counseling.
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6/j.bbmt.2010.08.019countries. The percentage of obese children has dou-
bled or tripled between the late 1970s and 2000,
from approximately 5% to 15% in the United States,
to 13.2% in the western region of the European
Union, and to 19.1% in the southern region of the
European Union [1,2]. This percentage remained
stable from 2000 to 2006 in the United States, with
15.5% of children at or above the 95th percentile for
body mass index (BMI) [3].
Obese adults with malignant diseases experience
more transplantation-related toxicity and worse over-
all and event-free survival compared with normal-
weight patients after autologous hematopoietic cell
transplantation (HCT) [4-6]. Similar outcomes also
have been observed after allogenic HCT in obese
adults [7]. More recently, a large retrospective study
demonstrated an increased risk of grade II-IV acute
graft-versus-host disease (aGVHD) and infectious
complications associated with obesity after transplan-
tation [8].
To date, few large-scale studies have addressed how
undernutrition and overnutrition affect transplantation737
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normal-weight children, underweight or obese children
have worse survival rates after chemotherapy for leuke-
mia [9,10]. Data after transplantation are scarce, with
1 report demonstrating no impact of obesity on
outcomes [7].
The aim of the present study is to assess the effect
of children’s BMI on bone marrow transplantation
outcomes. To best minimize potential confounders,
such as including malignant disease where weight can
be a surrogate of disease status at transplantation,
intensity or recovery from previous treatments, and
multiple types of conditioning regimens for different
diseases, a population of patients with severe aplastic
anemia (SAA) was selected.PATIENTS AND METHODS
Data Sources
The Center for International Blood and Marrow
Transplant Research (CIBMTR) is a voluntary work-
ing group of more than 450 transplantation centers
worldwide that contribute detailed data on consecutive
HCTs to a Statistical Center located at the Medical
College of Wisconsin in Milwaukee and the National
Marrow Program (NMDP) Coordinating Center in
Minneapolis. Participating centers are required to re-
port all transplantations consecutively; compliance is
monitored by onsite audits. The CIBMTR maintains
an extensive database of detailed patient-, transplant-,
and disease-related information for transplantations
performed worldwide and prospectively collects data
longitudinally with yearly follow-ups. Computerized
checks for discrepancies, physician review of submitted
data, and onsite audits of participating centers ensure
data quality. Observational studies conducted by the
CIBMTR are performed in compliance with HIPAA
regulations as a public health authority and also in
compliance with all applicable federal regulations per-
taining to the protection of human research partici-
pants, as determined by a continuous review by the
Institutional Review Boards of NMDP and the Medi-
cal College of Wisconsin.Patients
Our study population included pediatric patients
aged 2-19 years who underwent a first allogeneic
HCT for SAA between 1990 and 2005 reported to
the CIBMTR. A total of 1,354 patients met the initial
selection criteria. We excluded 37 patients from teams
with inadequate follow-up or inconsistent reporting
over the study period, to reduce selection and report-
ing bias of patients. This left 1,317 patients for inclu-
sion in the analysis. Corrective action plan (CAP)
modeling addresses the potential bias introduced bythe exclusion of nonconsenting surviving patients by
randomly excluding the same percentage of deceased
patients using a weighted randomized scheme. This
process is used to adjust for oversampling of dead pa-
tients in the consenting cohort [11]. CAP modeling
in this dataset excluded an additional 37 unrelated do-
nor patients. Our final study population included 860
HLA-matched siblings (Sibs) and 421 unrelated donor
(URD) transplant recipients from 91 reporting centers
worldwide.
Obesity has previously been defined based on
BMI in adults.This index has been validated and shown
tobe of utility in children aged 2-19 years for predicting
underweight, normal-weight, and overweight individ-
uals [12,13]. We divided the patients into 5 groups
based on their age-adjusted BMI. Age-adjusted BMIs
were calculated using 2000 Centers for Disease
Control and Prevention (CDC) BMI-for-age growth
charts to obtain percentile rankings, which were
then used as an indicator to assess the BMI of the
study population with reference to the general popula-
tion [14,15].Weight categorieswere defined as follows:
underweight, \5th percentile (n 5 109); at risk for
underweight, 5th percentile to\25th percentile (n 5
196); normal weight, 25th percentile to 75th percen-
tile (n 5 527); at risk for overweight, 76th percentile
to 95th percentile (n 5 306); and overweight, .95th
percentile (n 5 143). The sample size of this cohort
allowed us to include patients in the threshold
percentiles by adding groups at risk for underweight
and overweight, which could demonstrate a possible
dose–effect relationship of BMI and outcome.
Follow-up was updated for all patients in the data
file. Each patient enrolled in the study had a minimum
of 2 years of potential follow-up.Study Endpoints and Variables
Primary endpoints were 100-day mortality,
aGVHD grade III-IV, and overall survival (OS), with
100-day mortality defined as death from any cause on
or before day 100 posttransplantation. Patients alive
at last observation with fewer than 100 days of
follow-up were not considered at risk for this event.
aGVHD grade III-IV was defined using the Glucks-
berg system,which gradesGVHDbased on the pattern
and severity of abnormalities in skin, gastrointestinal
system, and liver [16]. This event was summarized by
the cumulative incidence estimate, with death and
second transplantation as competing risks. OS was
defined as time to death from any cause; surviving
patients were censored at time of last follow-up.
Variables selected for analysis included age (2-5 vs
6-10 vs 11-15 vs 16-19 years), Lansky performance
score ($90 vs\90 vs missing), donor–recipient cyto-
megalovirus (CMV) serology, race and ethnicity,
country or region, number of transfusions before
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from diagnosis to transplantation (\6 months vs $6
months), donor type and HLA matching (Sibs vs
URD matched, URD partially matched, and URD
mismatched, according to Weisdorf et al. [17]), condi-
tioning regimen (separately by donor type), year
of transplantation (1990-1993 vs 1994-1997, 1998-
2001, and 2002-2005), and GVHD prophylaxis
(cyclosporine/methotrexate vs T cell depletion,
cyclosporine 6 other, and tacrolimus 6 other).
Because the selection of conditioning regimens varied
depending on type of donor, conditioning regimens
used in Sibs and URD transplants were analyzed
separately.Statistical Analysis
Variables related to patient, disease, and transplant
characteristics were compared using the c2 test for
categorical variables and the Kruskal-Wallis test for
continuous variables. A P value of\.05 was considered
significant for differences among weight groups.
Univariate probabilities for OS and 100-day mortality
were calculated using the Kaplan-Meier estimator.
The univariate probability of aGVHD III-IV was
calculated using the cumulative incidence function,
with death as the competing risk [18].
In the multivariate analysis, a forward stepwise
Cox proportional hazards model was used to select
covariates for inclusion in the model [19]. Because
the primary objective was to compare the BMI per-
centile groups (main effect), we forced BMI into the
main model while selecting other covariates that
might affect that particular outcome. Models for
OS and aGVHD III-IV were fitted for URD and
HLA-identical sibling donors separately and then
combined because of their similar effects of baseline
weight on outcomes. Conditioning regimen was ana-
lyzed separately by donor type. Patient region and
race were entered into the models as interaction
terms for patients who underwent transplantation in
the United States and South America with available
race/ethnicity information. All variables were exam-
ined to ensure that they complied with the propor-
tional hazards assumption, and interactions with the
main effect were tested in the model. Comparison
across 5 distinct groups as the main effect required
adjustments for multiple comparisons. Bonferroni
corrections were applied to allow adjustment for mul-
tiple comparisons between each weight group and the
normal weight group. Thus, a P value \.0167 was
considered statistically significant, whereas the P
values for inclusion in the final models of all other
potentially confounding covariates were set at\.05.
All analyses were performed using SAS 9.2 (SAS
Institute, Cary, NC).RESULTS
Patient Characteristics
A total of 1,281 patients were included in the anal-
ysis. The number of patients in each weight category
was as follows: underweight, 109 (8.5%); at risk for un-
derweight, 196 (15.3%); normal weight, 527 (41.1%);
at risk for overweight, 306 (23.8%); overweight, 143
(11.1%). Patient characteristics are compared by
weight group in Table 1 and by donor type in Table
2. Obese patients more frequently received an URD
graft (18%URDvs 8%Sibs) and underwent transplan-
tation in the United States (60%). Underweight and at
risk for underweight patients were older than patients
in the other weight groups (P\ .01), and 66% of pa-
tients in these weight groups were from Europe, the
Middle East, and South America. The distribution of
Lansky performance scores at transplantation, previ-
ous transfusions, and time from diagnosis to transplan-
tation did not differ among weight groups. URD
transplants were performed more commonly after
1998. Compared with Sibs recipients, URD recipients
were more likely to undergo transplantation after
6 months from diagnosis and to receive total body
irradiation (TBI)-containing regimens.
Busulfan-containing regimens were used mostly in
HLA-matched donor transplantations from centers
outside the United States. Antithymocyte globulin
(ATG) was commonly used for both Sibs and URD
transplants, and cyclosporine and methotrexate were
the most common GVHD prophylaxis treatments,
used in 81% of Sibs transplants and in 50% of URD
transplants.Acute GVHD
The probability of aGVHD III-IV at day 100 was
8% (95% confidence interval [CI], 4%-14%] for
underweight patients, 8% (95% CI, 5%-13%) for at
risk of underweight patients, 11% (95% CI, 8%-14%)
for normal-weight patients, 15% (95% CI, 11%-19%)
for at risk of overweight patients, and 24% (95% CI,
18%-32%) for overweight patients (P\ .01). Multivar-
iate analysis of aGVHD III-IV adjusted for significant
covariates—race/ethnicity/region, donor type, HLA
matching, conditioning regimen (Sibs only), and
GVHD prophylaxis—resulted in a relative risk (RR)
of 1.55 (95%CI, 1.00-2.41; P5 .05) for the overweight
group compared with the normal-weight group. The
overall P value for BMI in the aGVHD III-IV model
was .15. The varying impacts of significant covariates
on the development of aGVHD III-IV are summarized
in Table 3. It is noteworthy that a reduced risk of
aGVHD III-IV was seen in children undergoing
transplantation in Asia (RR, 0.18; 95% CI, 0.06-0.61;
P \ .01) compared with Caucasian children in the
United States; and also in recipients of T cell–depleted
Table 1. Characteristics of Patients Who Underwent Allogeneic HCT for SAA between 1990 and 2005, by BMI Group
Characteristic Underweight
At Risk for
Underweight
Normal
Weight
At Risk for
Overweight Overweight P Value
Patient characteristics
Number of patients 109 196 527 306 143
Sib:URD ratio 2.6 :1 3:1 2.2:1 2:1 0.88:1
Age at transplantation, year, median (range) 12 (2-19) 12 (2-19) 12 (2-19) 11 (2-19) 10 (2-18) <.001
2-5 27 (25) 21 (11) 59 (11) 33 (11) 24 (17)
6-10 19 (17) 56 (29) 143 (27) 104 (34) 53 (37)
11-15 35 (32) 57 (29) 181 (34) 95 (31) 48 (34)
16-19 28 (26) 62 (32) 144 (27) 74 (24) 18 (13)
Male sex, n (%) 74 (68) 109 (56) 307 (58) 157 (51) 76 (53) .03
Lansky performance score $90, n (%) 70 (64) 132 (67) 355 (67) 193 (63) 92 (64) .58
Race/ethnicity, n (%) <.001
White 55 (50) 108 (55) 331 (63) 185 (60) 82 (57)
Black 7 (6) 18 (9) 40 (8) 26 (8) 10 (7)
Hispanic 3 (3) 5 (3) 27 (5) 21 (7) 21 (15)
Asian 13 (12) 33 (17) 65 (12) 39 (13) 12 (8)
Pacific Islander/Native American 3 (2) 0 6 (1) 0 4 (3)
Middle Eastern/North African 17 (16) 21 (11) 34 (6) 18 (6) 6 (4)
Mixed/unknown 10 (10) 11 (6) 19 (3) 15 (5) 8 (5)
Patient region, n (%) <.001
United States 28 (26) 58 (30) 175 (33) 98 (32) 86 (60)
Canada 5 (5) 12 ( 6) 31 (6) 15 (5) 9 (6)
Europe 14 (13) 41 (21) 111 (21) 64 (21) 13 (9)
Asia 14 (13) 22 (11) 56 (11) 38 (12) 10 (7)
Australia/New Zealand 3 (3) 3 ( 2) 21 (4) 14 (5) 7 (5)
Mideast/Africa 23 (21) 23 (12) 39 (7) 17 (6) 5 (3)
Central/South America 22 (20) 37 (19) 94 (18) 60 (20) 12 (8)
Year of transplantation, n (%) .41
1990-1993 26 (24) 50 (26) 144 (27) 75 (25) 26 (18)
1994-1997 36 (33) 53 (27) 172 (33) 92 (30) 49 (34)
1998-2001 24 (22) 45 (23) 114 (22) 71 (23) 42 (29)
2002-2005 23 (21) 48 (24) 97 (18) 68 (22) 26 (18)
Disease-related characteristics
Previous transfusions, n (%) 73 (67) 133 (68) 362 (69) 198 (65) 66 (46) <.001
Number of donor exposures, n (%) .004
<20 29 (27) 60 (31) 172 (33) 90 (29) 33 (23)
21-50 22 (20) 35 (18) 94 (18) 57 (19) 11 (8)
>50 18 (17) 33 (17) 72 (14) 42 (14) 17 (12)
Unknown 4 (4) 4 (2) 19 (4) 7 (2) 3 (2)
Median time from diagnosis to transplantation, months 4 3 4 5 8
<6 months, n (%) 65 (60) 137 (70) 311 (59) 163 (53) 61 (43) <.001
$6 months, n (%) 43 (39) 59 (30) 215 (41) 142 (46) 82 (57)
IST before HCT, n (%) 49 (45) 103 (53) 307 (58) 199 (65) 106 (74) <.001
Transplantation-related characteristics
Sibling donor, n (%) 79 (72) 147 (75) 363 (69) 204 (67) 67 (47) <.001
URD, n (%) 30 (28) 49 (25) 164 (31) 102 (33) 76 (53)
Well matched, n (%) 10 (9) 19 (10) 47 (9) 34 (11) 18 (13)
Partially matched, n (%) 12 (11) 15 (8) 49 (9) 31 (10) 29 (20)
Mismatched, n (%) 8 (7) 15 (8) 68 (13) 37 (12) 29 (20)
Donor–recipient CMV match, n (%) .41
Any positive 71 (65) 140 (72) 341(65) 211 (70) 92 (64)
Negative 30 (28) 42 (21) 154 (29) 79 (26) 46 (32)
Unknown 8 (7) 14 (7) 32 (6) 16 (5) 5 (3)
Conditioning regimen, n (%) .01
Cy ± other 28 (26) 47 (24) 142 (27) 70 (23) 19 (13)
Cy + TBI ± other 18 (17) 28 (14) 71 (13) 39 (13) 39 (27)
Cy + BU ± other 18 (17) 25 (13) 51 (10) 38 (12) 14 (10)
Cy + ATG ± other 44 (40) 92 (47) 257 (49) 156 (51) 70 (49)
TBI dosage #1,300 cGy 19 (17) 36 (18) 101 (19) 60 (20) 49 (34) <.001
ATG 53 (49) 98 (50) 276 (52) 169 (55) 76 (53) .72
GVHD prophylaxis, n (%) .36
T cell depletion 15 (14) 19 (10) 65 (12) 27 (9) 20 (14)
CSA + MTX ± other 75 (69) 140 (71) 389 (74) 216 (70) 95 (67)
CSA only 16 (15) 27 (14) 54 (11) 46 (15) 14 (10)
Tacrolimus ± other 3 (2) 6 (3) 11 (2) 9 (3) 9 (6)
Other – 4 (2) 8 (1) 8 (3) 5 (3)
Median follow-up of survivors, months 71 65 74 62 59
Bu indicates busulfan; CSA, cyclosporine; Cy, cyclophosphamide; IST, immune suppression therapy; MTX, methotrexate.
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Table 2. Characteristics of Patients Who Underwent Allogeneic HCT for SAA between 1990 and 2005 by Donor Type
Characteristic Sibs URD P Value
Number of patients 860 421
Lansky performance score $90, n (%) 532 (62) 310 (74) <.001
BMI group, n (%) <.001
Underweight 79 (9) 30 (7)
At risk for underweight 147 (17) 49 (12)
Normal weight 363 (42) 164 (39)
At risk for overweight 204 (24) 102 (24)
Overweight 67 (8) 76 (18)
Time from diagnosis to HCT, months median (range) 2 (<1-86) 16 (<1-150) <.001
<6 months, n (%) 669 (78) 68 (16)
$6 months, n (%) 191 (22) 350 (83)
Conditioning regimen, n (%) <.001
Cy ± other 283 (33) 23 (5)
Cy + TBI ± other 30 (3) 165 (39)
Cy + BU ± other 128 (15) 18 (4)
Cy + ATG ± other 410 (48) 209 (50)
GVHD prophylaxis, n (%) <.001
T cell depletion 16 (2) 130 (31)
CSA + MTX ± other 699 (81) 212 (50)
CSA only 123 (14) 34 (8)
Tacrolimus ± other 8 (1) 30 (7)
Other 14 (2) 15 (4)
Year of transplantation, n (%) <.001
1990-1993 254 (30) 67 (16)
1994-1997 289 (34) 113 (27)
1998-2001 177 (21) 119 (28)
2002-2005 140 (16) 122 (29)
Patient region, n (%) <.001
United States 142 (17) 303 (72)
Canada 52 (6) 20 (5)
Europe 180 (21) 63 (15)
Asia 122 (14) 18 (4)
Australia/New Zealand 37 (4) 11 (3)
Mideast/Africa 105 (12) 2 (<1)
Central/South America 222 (26) 3 (<1)
Follow-up of survivors, months, median (range) 74 (3-206) 58 (3-194)
Bu indicates busulfan; CSA, cyclosporine; Cy, cyclophosphamide; MTX, methotrexate.
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with recipients conditioned with cyclosporine/metho-
trexate. The risk for aGVHD III-IV was increased in
URD recipients compared with Sibs recipients regard-
less ofHLAmatching (Table 3). Among Sibs recipients,
the risk was greater in those receiving a busulfan-
containing regimen compared with those receiving
a cyclophosphamide and ATG combination (RR,
4.75; 95% CI, 1.88-12.02; P\ .01).
Survival Outcomes
Mortality at 100 days posttransplantation was
13% (95% CI, 7-20) for underweight patients, 15%
(95% CI, 10%-20%) for at risk of underweight
patients, 12% (95% CI, 9%-14%) for normal-weight
patients, 17% (95% CI, 13%-21%) for at risk of over-
weight patients, and 29% (95% CI, 22%-37%) for
overweight patients (P\ .01). Adjusted survival curves
according to weight group are summarized in Figure 1.
Multivariate analysis of mortality, which was adjusted
for race/ethnicity/region, donor type, HLA matching,
conditioning regimen (Sibs only), Lansky performance
score, and years after transplantation, resulted in anRR
of death of 1.71 (95% CI, 1.24-2.35; P\. 01) in over-
weight patients compared with normal-weightpatients. Figure 2 summarizes the magnitude of the
effect of weight on mortality across all groups.
The different impacts of significant covariates on
mortality are summarized in Table 3. It is noteworthy
that reduced mortality was observed in patients who
underwent transplantation between 2002 and 2005
compared with those who underwent transplantation
between 1990 and 1993 (RR, 0.44; 95% CI, 0.29-0.66;
P\ .01). Increased mortality was observed in African-
American recipients compared with Caucasian recipi-
ents in the United States (RR, 1.84; 95% CI,
1.17-2.91; P\ .01). Recipients of URD, regardless of
HLA matching (Table 3), and patients with Lansky
performance score of\90 at the time of transplantation
(RR, 1.71; 95% CI, 1.36-2.14; P\ .01). Mortality was
higher with Bu-containing conditioning regimens
compared to cyclophosphamide/ATG, among recipi-
ents of Sibs grafts (RR, 3.13; 95% CI. 1.85-5.29, P\
0.01).
Causes of Death
A total of 363 patients died during the course of the
study: 204 URD recipients (48%) and 159 Sibs recip-
ients (18%). The attributed causes of death reported
by transplant centers were infection (24%), graft
Table 3. Multivariate Analyses of aGVHD Grade III-IV and Mortality of Children with SAA Who Underwent Allogeneic HCT
between 1990 and 2005
Variable n aGVHD P Value Overall Mortality P Value
Age-adjusted BMI .147 .012
Underweight 108 0.7 (0.34-1.44) .332 1.01 (0.65-1.57) .972
At risk of underweight 196 0.84 (0.48-1.48) .551 1.38 (0.99-1.91) .057
Normal 525 1 1
At risk of overweight 304 1.09 (0.73-1.63) .673 1.22 (0.93-1.61) .142
Overweight 142 1.55 (1-2.41) .05 1.71 (0.24-2.35) .001
Race/region .02 .004
US, Caucasian 303 1 1
US, African American 50 1.61 (0.92-2.82) .09 1.84 (1.17-2.91) .01
US, Hispanic 47 1.09 (0.59-2.02) .78 1.13 (0.07-1.83) .61
US, Asian/Pacific Islander 24 0.63 (0.22-1.77) .38 0.46 (0.17-1.26) .13
US, Other 15 0.28 (0.04-2.04) .22 1.02 (0.41-2.53) .97
Canada 71 0.28 (0.1-0.8) .02 0.58 (0.32-1.07) .08
Europe 241 0.67 (0.41-1.1) .11 0.92 (0.65-1.31) .66
Asia 140 0.18 (0.06-0.61) .005 1.34 (0.85-22.11) .21
Australia/New Zealand 48 0.91 (0.35-2.33) .84 0.48 (0.22-1.04) .06
Middle East 107 1.09 (0.45-2.67) .84 1.6 (0.95-2.71) .08
South America, white 123 0.36 (0.12-1.04) .06 0.78 (0.44-1.38) .39
South America, black 43 0.53 (0.13-2.14) .37 1.64 (0.87-3.09) .13
South America, Hispanic 27 0.43 (0.66-3.25) .41 0.98 (0.38-2.53) .97
South America, unknown 31 0.34 (0.07-1.65) .18 1.06 (0.52-2.18) .87
Donor type, HLA matching <.001 <.001
Matched sibling donor 855 1 1
URD, matched 125 7.05 (3.52-14.11) <.001 4.8 (2.91-7.94) <.001
URD, partially matched 136 10.12 (5.34-19.2) <.001 8.36 (5.55-12.59) <.001
URD, mismatched 154 11.74 (6.17-22.33) <.001 7.99 (5.32-12) <.001
Conditioning regimen (sibling only) .01 <.001
Cy + ATG 407 1 1
TBI ± other 53 0.66 (0.14-3.14) .60 1.36 (0.68-2.75) .38
Bu ± other 133 4.75 (1.88-12.02) .001 3.13 (1.85-5.29) <.001
Cy ± other (no ATG) 262 1.51 (0.72-3.2) .28 1.92 (1.24-2.96) .003
GVHD prophylaxis <.001
CSA + MTX ± other 912 1 –
CSA ± other 165 2.57 (1.71-3.84) <.001 –
T cell depletion 144 0.32 (0.18-0.54) <.001 –
Tacrolimus ± other 37 1.13 (0.59-2.15) .72 –
Other 12 6.27 (1.33-29.69) .02 –
Lansky Performance Score – – <.001
$90 838 – – 1
<90 417 – – 1.71 (1.36-2.14) <.001
Missing 20 – – 2.48 (1.14-5.38) .02
Year of transplantation – – <.001
1990-1993 321 – – 1
1994-1997 400 – – 0.94 (0.7-1.26) .70
1998-2001 294 – – 0.77 (0.55-1.06) .11
2002-2005 260 – – 0.44 (0.29-0.66) <.001
Bu indicates busulfan; CSA, cyclosporine; Cy, cyclophosphamide; MTX, methotrexate.
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iopathic pneumonia syndrome (12%), hemorrhage
(9%), posttransplantation cancer (2%), and unknown
causes (4%). The most common cause of death was
infection in URD recipients (n 5 52; 25%), and graft
failure in Sibs recipients (n 5 37; 23%).DISCUSSION
Our data show that overweight children (age-ad-
justed BMI .95th percentile) with SAA experienced
worse survival outcomes after allogeneic HCT com-
pared with other children with SAA. This finding dem-
onstrates that obesity in this homogenous population
has a significant negative impact on survival and possi-bly also on complications post-HCT. Overweight
children with SAA have no apparent increase in the
rate of aGVHD III-IV.
The effect of body weight on transplantation out-
come has been the topic of several studies, with results
varying depending on the indication for transplanta-
tion, type of transplant, and patient population. This
question was initially addressed in recipients of autol-
ogous HCT for malignant diseases. Obese adults, de-
fined according to BMI, demonstrate higher mortality
after autologous HCT for non-Hodgkin lymphoma
and acute myelogenous leukemia (AML) [4,6].
Subsequent studies using the CIBMTR database
addressed this question in 4,681 adult recipients of
autologous HCT for lymphoma. Obese patients
experienced similar survival outcomes as overweight
Figure 1. Adjusted probability of OS of children with SAA who under-
went allogeneic HCT between 1990 and 2005, by weight group.
Figure 2. Multivariate analysis of overall mortality in children with SAA
who underwent allogeneic HCT between 1990 and 2005, by age-
adjusted BMI percentile.
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mortality was 2.5-fold greater for underweight pa-
tients compared with all other weight groups [5].
Similar results (ie, comparable survival outcomes of
obese and nonobese patients and shortened survival
in underweight patients) were found in patients with
AML receiving HCT [20]. Despite these observations
in a large cohort of patients, obesity was identified as
an independent prognostic factor for nonrelapse
mortality after HCT and is a component of the
HCT Comorbidity Index [21].
The results from obesity studies in the adult popu-
lation might not apply directly to children. The defini-
tion of obesity in adults uses a single BMImeasurement
at the time of transplantation. In children, age adjust-
ments are needed for defining weight groups, and
whether BMI in adults and age-adjusted BMI in
children have the same prognostic impact is uncertain.
Chemotherapy dose adjustments based on weight to
minimize toxicity are likely to differ between children
and adults [10]. Children with leukemia at the opposite
ends of the weight scale, overweight and underweight,
have higher mortality during standard chemotherapy
induction treatments [9,10]. Studies on the impact
of weight on posttransplantation outcomes in the
pediatric population are scant. One single-institution
study analyzed 54 children with BMI$ 95th percentile
among a cohort of 325 recipients of allogeneic HCT
for treatment of several diseases and found a 5-year
OS probability of 47% in the overweight group and
70% in the non-overweight group (P5 .02) [22].
The effect of obesity on aGVHD is less clear. Our
univariate analysis demonstrated a higher rate of
aGVHD III-IV in the overweight group, which was
likely related to the higher proportion of URD recipi-
ents in this group. After adjusting the analysis for donor
type and other variables, this effect of weight and
aGVHD III-IV disappeared.
A Japanese study of patients of all ages with malig-
nant diseases also found a strong relationship between
GVHD and weight at time of transplantation [8].Although in that study, univariate analysis demon-
strated a strong association between weight and both
aGVHD and chronic GVHD, this association disap-
peared in multivariate analysis. In our analysis, other
factors were strongly associated with development of
aGVHD III-IV in patients with SAA. As expected,
URD recipients and HLA disparity were associated
with higher rates of aGVHD III-IV. Recipients from
Asia experienced less frequent aGVHD III-IV, which
could be attributed to lower rates of aGVHD in
URD recipients in Asia due to less HLA gene variabil-
ity in that region.
Race and region also were associated with survival
outcome. Interestingly, mortality was higher in
African-American children compared with Caucasian
children in the United States. No data on socioeco-
nomic status, which could affect outcomes along
with access to care, were collected for these patients.
Improved survival outcomes in the later periods are at-
tributed to improvements in donor and patient selec-
tion, as has been described in previous studies [23].
The effect of conditioning regimen was analyzed sep-
arately in Sibs recipients and URD recipients. The use
of busulfan in Sibs recipients was associated with worse
survival. No effect of conditioning regimen and or of
survival outcome was seen in URD recipients.
The present study is the largest study to date con-
ducted to assess the effect of weight on outcomes of
allogeneic HCT in children with SAA. Nonetheless,
this is a retrospective study, using registry data span-
ning a 15-year period. The decision to proceed to
transplantation was made by individual transplant
physicians as part of center-specific protocols or as
a standard of care. Despite the large number of cases,
some variables (eg, dose-adjustment practices and
detailed previous treatment, including transfusion)
were not present in all patients and could not be
formally examined. Another limitation of this study
was the definition of obesity. The weight charts in
which the age-adjusted BMIs were calculated are nor-
malized to the US population, but the study used
744 Biol Blood Marrow Transplant 17:737-744, 2011C. C. Barker et al.children outside the United States as well. This might
explain the higher number of patients from Asia, South
America, and Europe in the underweight groups,
which could clarify why this group did not experience
poorer survival rates, as has been shown in other stud-
ies of underweight children. Small numbers of under-
weight children in the United States did not allow for
a meaningful subset analysis to address this question.
In conclusion, our study indicates that obese chil-
dren with SAA have a higher mortality rate after allo-
geneic HCT compared with normal-weight children.
There was no impact of weight on the development
of aGVHD III-IV in this population. Obesity is not
an easily modifiable risk factor, and optimizing nutri-
tion and weight pretransplantation is difficult due to
the urgency of the procedure. The impact of obesity
on transplantation outcomes for this disease should
be discussed during pretransplantation counseling.
Prospective studies with a better definition of obesity,
using anthropometrics in children, are important to
gaining more insight into the association between
obesity and posttransplantation outcomes.ACKNOWLEDGMENTS
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